
Traws Pharma (TRAW) Stock Forecast & Price Target
Traws Pharma (TRAW) Analyst Ratings
Bulls say
Traws Pharma is expected to see a positive outlook as the company secured capital and development funding, is advancing Tivoxavir marboxil into a human challenge study for influenza, and has potential with its other product candidates in treating COVID, hantavirus, and Ebola. Further potential upside could come from the success of Tivoxavir marboxil as a once-monthly influenza prophylaxis and its potential inclusion in the Strategic National Stockpile. While there are risks involved, such as financing, clinical trial, regulatory, delisting, and bankruptcy risks, the current market cap does not fully reflect the potential value of the company's pipeline and future success.
Bears say
Traws Pharma is facing financial challenges as a result of the negative review of their tivoxavir marboxil program by the MHRA, leading to a deferral of their planned human influenza challenge study. This setback limits the company's visibility for their next value driver and raises concerns about their ability to secure funding, given their cash runway only extends through 1Q27. Additionally, the decrease in the overall market for COVID therapeutics and the decreased emphasis on their COVID program suggest limited potential for financial success in the near future.
This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.
Traws Pharma (TRAW) Analyst Forecast & Price Prediction
Start investing in Traws Pharma (TRAW)
Order type
Buy in
Order amount
Est. shares
0 shares